Firefly Neuroscience (NASDAQ:AIFF) is a clinical‐stage neurotechnology company focused on developing digital biomarkers and cognitive assessment tools for the early detection and monitoring of neurological disorders. The company’s platform combines mobile applications, sensor technology and advanced analytics to capture objective brain function data outside of traditional clinical settings. By providing real‐world cognitive and physiological measurements, Firefly aims to improve diagnosis, track disease progression and support therapeutic development.
The company’s flagship offering is a smartphone‐based cognitive assessment app that guides users through a series of interactive tasks designed to measure attention, memory, processing speed and executive function. In select studies, Firefly has incorporated lightweight sensor headbands to record electroencephalogram (EEG) signals, enhancing its ability to derive neurophysiological biomarkers. These digital measures are intended both for clinical trial sponsors evaluating investigational treatments and for healthcare providers seeking earlier intervention strategies.
Founded in 2017 and headquartered in the Greater Boston area, Firefly Neuroscience initially focused on Alzheimer’s disease and other forms of age‐related cognitive decline. The company collaborates with academic research centers, pharmaceutical partners and patient advocacy organizations to validate its tools across diverse populations. While its early clinical programs have been U.S.‐based, Firefly has signaled plans to expand its research partnerships and regulatory engagement in Europe and Asia.
Firefly Neuroscience is led by a management team with backgrounds in neuroscience, medical device development and digital health innovation. Through its integrated hardware-software approach, the company seeks to redefine how brain health is assessed, moving beyond episodic, clinic-based testing to continuous, data-driven insights that can accelerate drug development and enhance patient care.
